Androlabs
Androlabs is a London-based pharmaceutical company and the first globally to focus exclusively on men's health. It markets testosterone replacement therapy and erectile dysfunction treatments through healthcare professionals, supported by the TRTed patient community and HCP education resources.
- Company typePrivate
- Founded2021
- HeadquartersLondon, United Kingdom
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Androlabs does
Androlabs is a London-based specialty pharmaceutical company, founded in 2021, that positions itself as the first global pharmaceutical firm dedicated exclusively to men's health. Its commercial portfolio is built on two therapeutic pillars: testosterone replacement therapy (TRT) for men with low testosterone, and pharmaceutical treatments for erectile dysfunction. Products are sold under the Androlabs brand through healthcare-professional channels — the company runs a dedicated, gated Healthcare Professional Zone offering CPD, research summaries, podcasts and patient resources — rather than via direct-to-consumer retail, indicating an enterprise/B2B motion to prescribers, urologists, endocrinologists and pharmacies.
The company's business model is straightforward specialty-pharma product sales to healthcare providers and, through them, to patients. Pricing is not publicly disclosed and is handled via a supply query channel ([email protected]), consistent with negotiated distribution arrangements rather than list-price retail. Revenue mechanics therefore depend on supply agreements, prescriber uptake and geographic rollout rather than on per-seat software contracts or subscription pricing.
Beyond the core pharmaceutical offering, Androlabs invests in a complementary ecosystem: the TRTed community (trted.org), an evidence-based online community for men addressing knowledge gaps in men's health, and 'The Brothers' Arms' newsletter. The stated strategic intent — articulated on the company website — is to expand the product offering beyond TRT and ED to cover a broader set of men's health indications. Headcount is reported at 11–50 employees; no funding rounds, investors, revenue figures, named customers, patents, awards, partnerships or leadership team details beyond the two founders (Charlie Bryant, co-founder; Nicolas Vennin, founder) are disclosed in the available material.
Androlabs firmographics
Firmographics- Name
- Androlabs
- Legal name
- Androlabs
- Website
- https://andro-labs.com
- Company type
- Private
- Founded year
- 2021
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Androlabs is a London-based pharmaceutical company and the first globally to focus exclusively on men's health. It markets testosterone replacement therapy and erectile dysfunction treatments through healthcare professionals, supported by the TRTed patient community and HCP education resources.
- Ownership category
- akta.pro rank
Androlabs industry classification
Industry- Product category
- Men's Health Pharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health) (HLAIAAAJ)
- akta.pro secondary industries
- Nephrology & Urology Specialty Pharmaceuticals (HLAIACAH), Male Reproductive & Sexual Medicine (Andrology) (HLAKAOAD)
Keywords
Where Androlabs is headquartered
LocationHeadquarters
- HQ city
- London
- HQ country
- United Kingdom
- HQ region
- Europe
Offices1 record
Markets served
Androlabs business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Operations, Supply Chain, Technology or R&D, Marketing or Sales
Revenue model
- Pharmaceutical Product Sales: Androlabs generates revenue through the sale of pharmaceutical products including testosterone replacement therapy and erectile dysfunction medications. As a pharmaceutical company, revenue is derived from product sales to healthcare providers and patients.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
Androlabs product offering
Product offeringCore offering
Androlabs is the first global pharmaceutical company solely focused on men's health, developing and commercializing Testosterone Replacement Therapy (TRT) and Erectile Dysfunction (ED) therapies. Its portfolio is supported by an Education & Support function and the TRTed patient community, with a dedicated Healthcare Professional Zone serving clinicians and prescribers.
Product overview
Androlabs is the first global pharmaceutical company dedicated to men's health, operating as a single-brand pharmaceutical company. The company offers a portfolio centered on two core therapeutic areas: Testosterone Replacement Therapy and Erectile Dysfunction Therapies. These pharmaceutical products are supported by complementary Education & Support services and the TRTed Community platform, which provides evidence-based resources and a community forum for men dealing with men's health issues. The portfolio is designed to address the male life expectancy gap through comprehensive pharmaceutical and educational offerings.
Differentiator
Problem solved
Functional benefit
Brands
- TRTed: An inclusive community dedicated to addressing knowledge gaps and providing evidence-based resources on men's health issues.
Products and services
- Testosterone Replacement Therapy Pharmaceutical therapy for men with testosterone deficiency, prescribed and dispensed through healthcare professionals and medical institutions as part of Androlabs' men's health portfolio.
- Erectile Dysfunction Therapies Pharmaceutical treatments for erectile dysfunction in men, prescribed and dispensed through healthcare professionals and medical institutions as part of Androlabs' men's health portfolio.
Companies that use Androlabs
Customer profileSegments2 records
Ideal customer profiles2 records
Androlabs technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Androlabs partnerships and signals
Strategic signalRecent moves5 records
Expansion highlights5 records
Androlabs competitors and assessment
Company assessmentMarket position
Strengths1 record
Weaknesses1 record
Competitive moat3 records
Key risks6 records
Key highlights6 records
Customer concentration
Androlabs social profiles
Digital presenceAndrolabs financial estimates
Financial estimateRevenue estimate
Valuation estimate
Androlabs leadership team
Management profileNumber of profiles
Profiles2 records
Androlabs funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Androlabs M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Androlabs
What does Androlabs do?
Androlabs is the first global pharmaceutical company solely focused on men's health, developing and commercializing Testosterone Replacement Therapy (TRT) and Erectile Dysfunction (ED) therapies. Its portfolio is supported by an Education & Support function and the TRTed patient community, with a dedicated Healthcare Professional Zone serving clinicians and prescribers.
Is Androlabs a public or private company?
Androlabs is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Androlabs founded?
Androlabs was founded in 2021. It employs 11 to 50 people.
Where is Androlabs based?
Androlabs is headquartered in London, United Kingdom, in the Europe region.
How does Androlabs make money?
One revenue line is on record: pharmaceutical Product Sales.
Does Androlabs have an API?
No public API is recorded for Androlabs.
What industry is Androlabs in?
Androlabs's product category is Men's Health Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAJ, Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health), with a secondary code of HLAIACAH, Nephrology & Urology Specialty Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.